Alicia Dickeson
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 61.1% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $10,483, more than ten times the $93 reported in 2023. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $54.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Boston Scientific$2K
- Foundation Fusion Solutions, LLC$343
- AstraZeneca$308
- Biotronik NRO, Inc.$301
- Globus Medical$224
- plus $1K from 21 others
What the payments were for
- Travel & lodging$5,62248%
- Food & beverage$5,76249%
- Education$3323%
- Entertainment$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 110 | $7,187 |
| Boston Scientific | 10 | $1,959 |
| Foundation Fusion Solutions, LLC | 5 | $343 |
| AstraZeneca | 11 | $308 |
| Biotronik NRO, Inc. | 10 | $301 |
| Globus Medical | 4 | $224 |
| Jazz Pharmaceuticals Inc. | 6 | $209 |
| Grifols USA, LLC | 7 | $133 |
| GSK | 7 | $129 |
| Mylan Specialty L.p. | 7 | $101 |
| Valinor Pharma, LLC | 5 | $92 |
| Sanofi | 5 | $92 |
| Collegium Pharmaceutical, Inc. | 4 | $89 |
| Boehringer Ingelheim | 4 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| SPR Therapeutics, Inc | 3 | $65 |
| Saluda Medical Americas, Inc. | 3 | $65 |
| Tersera Therapeutics LLC | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Protega Pharmaceutials Inc | 1 | $41 |
| Electromed, Inc. | 2 | $35 |
| Vertex | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Curonix LLC | 1 | $17 |
| Innovation Technologies Inc | 1 | $17 |
| Si-bone, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$2,724
- WaveWriter Alpha Prime 16$1,659
- INCEPTIV$1,400
- INTELLIS ADAPTIVESTIM$825
- GENERAL PAIN MANAGEMENT$144
- Senza$123
- Prospera$100
How this compares
$11,758 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 176 | $231,829 |
| WakixPitolisant Hcl | 13 | $95,219 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $87,417 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $75,739 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $56,466 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $29,692 |
| Spiriva RespimatTiotropium Bromide | 21 | $22,503 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $11,458 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 284 | $10,806 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,354 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $8,694 |
| Ventolin HfaAlbuterol Sulfate | 36 | $4,157 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $3,548 |
| Roflumilast | 11 | $1,485 |
| Azelastine Hcl | 38 | $766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $129 | $337,260290 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $88 | $109,920100 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $308 | $78,27879 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Ocala
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.